Physician profile
Robert S Valet
NPI 1780731661
$4,767.28
in general payments reported to CMS, 2019-2025
31 companies · $39.29 in 2025
The $39.29 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $566 · 2020: $614 · 2021: $717 · 2022: $951 · 2023: $879 · 2024: $1,000 · 2025: $39.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,861 · Education: $57.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,860.64 |
| Education | $57.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $700.05 | 2019-2024 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $539.75 | 2019-2024 | Tezspire, Fasenra, Airsupra |
| Pfizer INC. | $522.69 | 2019-2024 | |
| Abbvie INC. | $447.57 | 2019-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $352.73 | 2019-2024 | |
| Amgen INC. | $281.42 | 2020-2024 | Tezspire, Otezla |
| Sun Pharmaceutical Industries INC. | $274.99 | 2020-2024 | Ilumya |
| Glaxosmithkline, LLC. | $260.04 | 2019-2023 | Nucala, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $186.32 | 2019-2022 | |
| Janssen Biotech, INC. | $177.23 | 2020-2024 | Tremfya |
| Csl Behring | $168.92 | 2019-2024 | Haegarda, Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $150.44 | 2020-2023 | Hyqvia, Cuvitru |
| Genentech USA, INC. | $100.72 | 2022-2024 | Xolair |
| Incyte Corporation | $68.75 | 2021-2023 | Opzelura |
| Octapharma USA, INC. | $59.88 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $59.12 | 2022-2024 | Xembify |
| Alk-Abello, INC | $56.04 | 2021-2024 | Timothy, Standardized, Alternaria Tenuis, Standardized Mite D. Farinae |
| Shire North American Group INC | $53.06 | 2019 | |
| Phadia US INC. | $47.60 | 2022-2024 | Immunocap |
| Lilly USA, LLC | $42.63 | 2019 | |
| Leo Pharma INC. | $35.66 | 2020-2022 | |
| Pharming Healthcare, INC. | $23.12 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.60 | 2020 | |
| Ucb, INC. | $21.83 | 2025 | Bimzelx |
| Celgene Corporation | $19.68 | 2019 | |
| Dermira, INC. | $19.65 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.01 | 2023 | Cyltezo |
| Teva Pharmaceuticals USA, INC. | $16.96 | 2019 | |
| Mayne Pharma Commercial LLC | $14.56 | 2020 | |
| Promius Pharma LLC | $13.44 | 2019 | |
| Merck Sharp & Dohme LLC | $11.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Valet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.